Concomitant Essential Thrombocythemia and Mature B -Lymphoproliferative Disorder in a Patient

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts.
• Progression to myelofibrosis and other hematologic malignancies can occur, necessitating careful monitoring and management.
• Mature B-lymphoproliferative disorders can coexist or arise secondary to myeloproliferative neoplasms.

Observation:

• A 64-year-old male presented with constitutional symptoms, lymphadenopathy, and splenomegaly.
• Laboratory findings revealed marked leukocytosis, thrombocytosis, elevated LDH, and a leukoerythroblastic peripheral blood picture.
• Bone marrow biopsy showed increased lymphoid cells, myeloid precursors, megakaryocytes, and grade MF-2 reticulin fibrosis.

Findings:

• Immunohistochemistry and flow cytometry confirmed an increase in B-lymphocytes with lambda light chain restriction.
• The presence of a Janus Kinase 2 (JAK 2) mutation, with BCR-ABL1 translocation negative, supported the diagnosis.
• The patient was diagnosed with essential thrombocythemia progressing to myelofibrosis and a mature B-lymphoproliferative disorder.

Implications:

• This case highlights the complex and evolving nature of myeloproliferative neoplasms.
• The successful management with ruxolitinib suggests its potential efficacy in managing such complex hematologic disorders.
• Further research into the interplay between ET, myelofibrosis, and B-lymphoproliferative disorders is warranted.